82_FR_17335 82 FR 17268 - Government-Owned Inventions; Availability for Licensing

82 FR 17268 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 67 (April 10, 2017)

Page Range17268-17269
FR Document2017-07058

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 67 (Monday, April 10, 2017) 
[Federal Register Volume 82, Number 67 (Monday, April 10, 2017)]
[Notices]
[Pages 17268-17269]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-07058]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by 
communicating with the indicated licensing contact James M. Robinson at 
the Technology Transfer and Intellectual Property Office, National 
Institute of Allergy and

[[Page 17269]]

Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follows.

Compositions and Methods for Detecting Loa Loa

    Description of Technology: Loa loa is a filarial nematode estimated 
to infect 3-13 million people in Central and Western Africa. In parts 
of Africa, mass administration of ivermectin is common for 
onchocerciasis and lymphatic filariasis control. However, some 
individuals infected with Loa loa microfilariae in high densities are 
known to experience post-ivermectin severe adverse events, such as 
encephalopathy, coma, or even death. Therefore, diagnostic tools that 
can accurately identify and differentiate Loa loa microfilariae from 
other filarial infections are needed. Microscopic evaluation of blood 
samples is the only current diagnostic method used to detect Loa loa 
microfilaremia in endemic areas, and is impractical for widespread 
screening. Molecular based assays are useful and are quantitative, but 
require the use of sophisticated instrumentation.
    The inventors analyzed samples from Loa loa infected patients and 
uninfected controls, and have identified Loa loa microfilaria-specific 
antigens. The pending application claims a variety of means of 
detecting these antigens.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications:
     Diagnostics
Competitive Advantages:
     Highly specific to Loa loa microfilariae
     Highly sensitive
     Both diagnostic and quantitative
     Works with blood, urine, or saliva sample
Development Stage:
     Pre-Clinical

    Inventors: Thomas B. Nutman, NIAID, NIH; Sasisekhar Bennuru, NIAID, 
NIH; and Papa Makhtar Drame, NIAID, NIH.
    Publications: Drame, Papa, et al. 2016. Identification and 
Validation of Loa loa Microfilaria-Specific Biomarkers: A Rational 
Design Approach Using Proteomics and Novel Immunoassays. mBio, vol. 7 
no. 1 e02132-15.
    Intellectual Property: HHS Reference No. E-140-2015/0--US 
Provisional Patent Application No. 62/153,654 filed April 28, 2015; PCT 
Patent Application No. PCT/US2016/029673 filed April 28, 2016.
    Licensing Contact: James M. Robinson, 301-761-7542; 
[email protected].
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further develop, evaluate or commercialize a 
diagnostic means for detecting Loa loa microfilaria-specific antigens. 
For collaboration opportunities, please contact James M. Robinson, 301-
761-7542; [email protected].

    Dated: March 28, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-07058 Filed 4-7-17; 8:45 am]
 BILLING CODE 4140-01-P

17268 Federal Register / Vol. 82, No. 67 / Monday, April 10, 2017 / Notices needs of professionals caring for MD 20852; tel. 301–496–2644. A signed • Diagnostics children in disasters since the 2011 Confidential Disclosure Agreement will • Vaccines National Center for Disaster Medicine be required to receive copies of • Development of therapeutics and Public Health Conference on this unpublished patent applications. Competitive Advantages: topic. We will post modifications to the SUPPLEMENTARY INFORMATION: • Use in development of flavivirus agenda on the NACCD May 5, 2017 Technology description follows. vaccines meeting Web page, which is located at • Virus growth in various cell lines https://www.phe.gov/naccd. A Full-Length Infectious cDNA Clone of • Developing and developed world Availability of Materials: We will post Zika Virus From the 2015 Epidemic in research tool all meeting materials prior to the Brazil as a Genetic Platform for Studies Development Stage: meeting on the NACCD May 5, 2017 of Virus-Host Interactions and Vaccine • Research materials meeting Web page located at https:// Development Inventors: Alexander Pletnev (NIAID), www.phe.gov/naccd. Description of Technology: An Konstantin Tsetsarkin (NIAID). Procedures for Providing Public Input: arthropod-borne virus, Zika virus Intellectual Property: HHS Reference Members of the public may attend the (ZIKV), has recently emerged as a major No. E–114–2017/0. teleconference using a toll-free call-in human pathogen. Associated with Licensing Contact: Peter Soukas, J.D., phone number available on the NACCD complications during perinatal 301–594–8730; peter.soukas@nih.gov. Web site at https://www.phe.gov/naccd. development and Guillain-Barré Collaborative Research Opportunity: We encourage members of the public to syndrome in adults, ZIKV raises new The National Institute of Allergy and provide written comments that are challenges for understanding the Infectious Diseases is seeking statements relevant to the NACCD teleconference molecular determinants of flavivirus of capability or interest from parties prior to May 5, 2017. Send written pathogenesis. This underscores the interested in collaborative research to comments by email via the ‘‘Contact necessity for the development of a further develop, evaluate or Us’’ link on https://www.phe.gov/naccd reverse genetic system based on an commercialize vaccine(s) or diagnostics with ‘‘NACCD Public Comment’’ in the epidemic ZIKV strain. This technology for prophylaxis against flavivirus subject line. The NACCD will respond relates to the generation and infections. For collaboration to comments received by close-of- characterization in cell cultures of an opportunities, please contact Peter business April 28, 2017, during the infectious cDNA clone of ZIKV isolated Soukas, J.D., 301–594–8730; meeting. from the 2015 epidemic in Brazil. The peter.soukas@nih.gov. Dated: April 4, 2017. cDNA-derived ZIKV replicated Dated: March 23, 2017. George W. Korch Jr., efficiently in a variety of cell lines, Suzanne Frisbie, Acting Assistant Secretary for Preparedness including those of both neuronal and Deputy Director, Technology Transfer and and Response. placental origin. It was observed that the Intellectual Property Office, National Institute [FR Doc. 2017–07052 Filed 4–7–17; 8:45 am] growth of cDNA-derived virus was of Allergy and Infectious Diseases. BILLING CODE P attenuated compared to the growth of [FR Doc. 2017–07057 Filed 4–7–17; 8:45 am] the parental isolate in most cell lines, BILLING CODE 4140–01–P which correlates with substantial DEPARTMENT OF HEALTH AND differences in sequence heterogeneity HUMAN SERVICES between these viruses that were DEPARTMENT OF HEALTH AND determined by deep-sequencing HUMAN SERVICES National Institutes of Health analysis. Moreover, these results indicate that caution should be National Institutes of Health Government-Owned Inventions; exercised when interpreting the results Availability for Licensing of reverse-genetics experiments in Government-Owned Inventions; attempts to accurately predict the Availability for Licensing AGENCY: National Institutes of Health, HHS. biology of natural viruses. Finally, a AGENCY: National Institutes of Health, ACTION: Notice. Vero cell-adapted cDNA clone of ZIKV HHS. was generated that can be used as a ACTION: Notice. SUMMARY: The invention listed below is convenient platform for studies aimed at owned by an agency of the U.S. the development of ZIKV vaccines (live SUMMARY: The inventions listed below Government and is available for attenuated and inactivated) and are owned by an agency of the U.S. licensing to achieve expeditious therapeutics. Government and are available for commercialization of results of This technology is available for licensing to achieve expeditious federally-funded research and licensing nonexclusively in accordance commercialization of results of development. Foreign patent with 35 U.S.C. 209 and 37 CFR part 404, federally-funded research and applications are filed on selected as well as for further development and development. Foreign patent inventions to extend market coverage evaluation under a research applications are filed on selected for companies and may also be available collaboration. inventions to extend market coverage for licensing. This technology is further described for companies and may also be available FOR FURTHER INFORMATION CONTACT: in Tsetsarkin et al., ‘‘A Full-Length for licensing. asabaliauskas on DSK3SPTVN1PROD with NOTICES Licensing information and copies of the Infectious cDNA Clone of Zika Virus FOR FURTHER INFORMATION CONTACT: patent applications listed below may be from the 2015 Epidemic in Brazil as a Licensing information and copies of the obtained by communicating with the Genetic Platform for Studies of Virus- U.S. patent applications listed below indicated licensing contact Peter Soukas Host Interactions and Vaccine may be obtained by communicating at the Technology Transfer and Development,’’ mBio. 2016 Jul–Aug; with the indicated licensing contact Intellectual Property Office, National 7(4): e01114–16. Published online 2016 James M. Robinson at the Technology Institute of Allergy and Infectious Aug 23. doi: 10.1128/mBio.01114–16. Transfer and Intellectual Property Diseases, 5601 Fishers Lane, Rockville, Potential Commercial Applications: Office, National Institute of Allergy and VerDate Sep<11>2014 20:02 Apr 07, 2017 Jkt 241001 PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 E:\FR\FM\10APN1.SGM 10APN1

Federal Register / Vol. 82, No. 67 / Monday, April 10, 2017 / Notices 17269 Infectious Diseases, 5601 Fishers Lane, Patent Application No. 62/153,654 filed DEPARTMENT OF HEALTH AND Rockville, MD 20852; tel. 301–496– April 28, 2015; PCT Patent Application HUMAN SERVICES 2644. A signed Confidential Disclosure No. PCT/US2016/029673 filed April 28, Agreement will be required to receive 2016. National Institutes of Health copies of unpublished patent Licensing Contact: James M. National Heart, Lung, and Blood applications. Robinson, 301–761–7542; Institute; Notice of Meeting SUPPLEMENTARY INFORMATION: James.Robinson4@nih.gov. Technology descriptions follows. Pursuant to section 10(a) of the Collaborative Research Opportunity: Compositions and Methods for The Technology Transfer and Federal Advisory Committee Act, as Detecting Loa Loa Intellectual Property Office (TTIPO) is amended (5 U.S.C. App.), notice is Description of Technology: Loa loa is seeking parties interested in hereby given of a meeting of the Sleep a filarial nematode estimated to infect collaborative research to further Disorders Research Advisory Board. 3–13 million people in Central and develop, evaluate or commercialize a The meeting will be open to the Western Africa. In parts of Africa, mass diagnostic means for detecting Loa loa public, with attendance limited to space administration of ivermectin is common microfilaria-specific antigens. For available. Individuals who plan to for onchocerciasis and lymphatic collaboration opportunities, please attend and need special assistance, such filariasis control. However, some contact James M. Robinson, 301–761– as sign language interpretation or other individuals infected with Loa loa 7542; James.Robinson4@nih.gov. reasonable accommodations, should microfilariae in high densities are notify the Contact Person listed below known to experience post-ivermectin Dated: March 28, 2017. in advance of the meeting. severe adverse events, such as Suzanne Frisbie, Name of Committee: Sleep Disorders encephalopathy, coma, or even death. Deputy Director, Technology Transfer and Research Advisory Board. Therefore, diagnostic tools that can Intellectual Property Office, National Institute Date: June 22–23, 2017. accurately identify and differentiate Loa of Allergy and Infectious Diseases. Time: June 22, 2017, 1:00 p.m. to 5:00 p.m. loa microfilariae from other filarial [FR Doc. 2017–07058 Filed 4–7–17; 8:45 am] Agenda: Update on NIH sleep disorders infections are needed. Microscopic BILLING CODE 4140–01–P research programs and initiatives, updates on evaluation of blood samples is the only sleep related activities from selected Federal current diagnostic method used to Agency partners, and discussion of the NIH detect Loa loa microfilaremia in DEPARTMENT OF HEALTH AND Sleep Disorders Research Plan. endemic areas, and is impractical for HUMAN SERVICES Place: National Institutes of Health, Two widespread screening. Molecular based Rockledge Center, Conference Room 9100/ assays are useful and are quantitative, National Institutes of Health 9104, 6701 Rockledge Drive, Bethesda, MD but require the use of sophisticated 20892. instrumentation. Office of the Director; Notice of Charter Time: June 23, 2017, 8:00 a.m. to 3:00 p.m. The inventors analyzed samples from Renewal Agenda: Discussion and updates on the Loa loa infected patients and uninfected NIH Sleep Disorders Research Plan, and potential directions for inter-agency controls, and have identified Loa loa In accordance with Title 41 of the coordination activities. microfilaria-specific antigens. The U.S. Code of Federal Regulations, Place: National Institutes of Health, Two pending application claims a variety of Section 102–3.65(a), notice is hereby Rockledge Center, Conference Room 9100/ means of detecting these antigens. given that the Charter for the Center for 9104, 6701 Rockledge Drive, Bethesda, MD This technology is available for Scientific Review Advisory Council 20892. licensing for commercial development (CSRAC) was renewed for an additional Contact Person: Michael J. Twery, Ph.D., in accordance with 35 U.S.C. 209 and 37 two-year period on March 31, 2017. Director, National Center on Sleep Disorders CFR part 404, as well as for further Research, Division of Lung Diseases, National development and evaluation under a It is determined that the CSRAC is in Heart, Lung, and Blood Institute, National research collaboration. the public interest in connection with Institutes of Health, 6701 Rockledge Drive, Potential Commercial Applications: the performance of duties imposed on Suite 10170, Bethesda, MD 20892–7952, 301– • Diagnostics the National Institutes of Health by law, 435–0199, twerym@nhlbi.nih.gov. Competitive Advantages: and that these duties can best be Information is also available on the • Highly specific to Loa loa performed through the advice and Institute’s/Center’s home page: https:// microfilariae counsel of this group. www.nhlbi.nih.gov/about/committees/sdrab/, • Highly sensitive Inquiries may be directed to Jennifer where an agenda and any additional • Both diagnostic and quantitative information for the meeting will be posted • Works with blood, urine, or saliva Spaeth, Director, Office of Federal when available. sample Advisory Committee Policy, Office of (Catalogue of Federal Domestic Assistance Development Stage: the Director, National Institutes of Program Nos. 93.233, National Center for • Pre-Clinical Health, 6701 Democracy Boulevard, Sleep Disorders Research; 93.837, Heart and Inventors: Thomas B. Nutman, NIAID, Suite 1000, Bethesda, Maryland 20892 Vascular Diseases Research; 93.838, Lung NIH; Sasisekhar Bennuru, NIAID, NIH; (Mail Code 4875), Telephone (301) 496– Diseases Research; 93.839, Blood Diseases 2123, or spaethj@od.nih.gov. and Resources Research, National Institutes asabaliauskas on DSK3SPTVN1PROD with NOTICES and Papa Makhtar Drame, NIAID, NIH. Publications: Drame, Papa, et al. 2016. of Health, HHS) Dated: April 4, 2017. Identification and Validation of Loa loa Michelle Trout, Dated: April 4, 2017. Microfilaria-Specific Biomarkers: A Rational Design Approach Using Program Analyst, Office of Federal Advisory Michelle Trout, Proteomics and Novel Immunoassays. Committee Policy. Program Analyst, Office of Federal Advisory mBio, vol. 7 no. 1 e02132–15. [FR Doc. 2017–07054 Filed 4–7–17; 8:45 am] Committee Policy. Intellectual Property: HHS Reference BILLING CODE 4140–01–P [FR Doc. 2017–07056 Filed 4–7–17; 8:45 am] No. E–140–2015/0—US Provisional BILLING CODE 4140–01–P VerDate Sep<11>2014 20:02 Apr 07, 2017 Jkt 241001 PO 00000 Frm 00092 Fmt 4703 Sfmt 9990 E:\FR\FM\10APN1.SGM 10APN1


Document Created: 2017-04-08 03:31:23
Document Modified: 2017-04-08 03:31:23
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact James M. Robinson at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 17268 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR